This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (164)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular Intervention  • Thrombolysis  • Adverse Effects  • Alert me on articles by topic

Elaine M. Hylek, MD, MPH; Heather Heiman, BS; Steven J. Skates, PhD; Mary A. Sheehan, RN; Daniel E. Singer, MD

JAMA. 1998;279:657-662.

Context.— Warfarin is highly effective in preventing thromboembolism, but increases the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0. Identifying causes of excessive anticoagulation in clinical practice could help target patients at risk for elevated INRs.

Objective.— To determine causes of INRs greater than 6.0 in a clinical practice setting.

Design.— Case-control study.

Setting.— Outpatient anticoagulant therapy unit.

Patients.— Outpatients followed up prospectively from April 1995 to March 1996 who had been taking warfarin for more than 1 month, had a target INR of 2.0 to 3.0, and were able to be interviewed within 24 hours of their reported INR. Case patients had INRs greater than 6.0; controls were randomly selected from patients having INRs between 1.7 and 3.3.

Main Outcome Measures.— Factors associated with INRs greater than 6.0, including medication use, recent diet, illness, alcohol consumption, and actual warfarin use.

Results.— A total of 93 cases and 196 controls were interviewed; they did not differ in age, indication for warfarin, length of therapy, warfarin dose, number of prescription medications, or previous INR or long-term INR variability. Acetaminophen ingestion was independently associated in a dose-dependent manner with having an INR greater than 6.0 (P for trend <.001). For the highest-dose category of acetaminophen intake, 9100 mg/wk or more, the odds of having an INR greater than 6.0 were increased 10-fold (95% confidence interval [CI], 2.6-37.9). Other factors independently associated with an INR greater than 6.0 were new medication known to potentiate warfarin (odds ratio [OR], 8.5; 95% CI, 2.9-24.7), advanced malignancy (OR, 16.4; 95% CI, 2.4-111.0), recent diarrheal illness (OR, 3.5; 95% CI,1.4-8.6), decreased oral intake (OR, 3.6; 95% CI, 1.3-9.7), and taking more warfarin than prescribed (OR, 8.1; 95% CI, 2.2-30.0). Higher vitamin K intake (OR, 0.7; 95% CI, 0.5-0.9) and habitual alcohol consumption of from 1 drink every other day to 2 drinks a day (OR, 0.2; 95% CI, 0.1-0.7) were associated with decreased risk.

Conclusions.— These data suggest that acetaminophen is an underrecognized cause of overanticoagulation in the outpatient setting. Several other clinically important risk factors were identified. Increased monitoring of INR values when such risk factors are present or modification of the risk factors themselves should reduce the frequency of dangerously high levels of anticoagulation.

From the General Medicine Division, Clinical Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.

RELATED ARTICLE

Acetaminophen and Warfarin: Undesirable Synergy
William R. Bell
JAMA. 1998;279(9):702-703.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT | FULL TEXT  

Too high a pedestal
Aronson
BMJ 2008;336:735-735.
FULL TEXT  

Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial
Dentali et al.
The Annals of Pharmacotherapy 2006;40:1241-1247.
ABSTRACT | FULL TEXT  

Reducing warfarin medication interactions: an interrupted time series evaluation.
Feldstein et al.
Arch Intern Med 2006;166:1009-1015.
ABSTRACT | FULL TEXT  

Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression
van Walraven et al.
Chest 2006;129:1155-1166.
ABSTRACT | FULL TEXT  

Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin: Assessment of Incidence, Case-Fatality Rate, Time Course and Sites of Bleeding, and Risk Factors for Bleeding.
Douketis et al.
Arch Intern Med 2006;166:853-859.
ABSTRACT | FULL TEXT  

Interaction between paracetamol and oral anticoagulants
Ornetti et al.
Rheumatology (Oxford) 2005;44:1584-1585.
FULL TEXT  

Systematic Overview of Warfarin and Its Drug and Food Interactions
Holbrook et al.
Arch Intern Med 2005;165:1095-1106.
ABSTRACT | FULL TEXT  

Emerging therapies for stroke prevention in atrial fibrillation
O'Donnell et al.
Eur Heart J Suppl 2005;7:C19-C27.
ABSTRACT | FULL TEXT  

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population
Jones et al.
Heart 2005;91:472-477.
ABSTRACT | FULL TEXT  

Late-Life Alcoholism: Issues Relevant to the Geriatric Psychiatrist
Oslin
AJGP 2004;12:571-583.
ABSTRACT | FULL TEXT  

Treatment of Patients With Arthritis-Related Pain
DeAngelo and Gordin
JAOA: Journal of the American Osteopathic Association 2004;104:2S-5S.
ABSTRACT | FULL TEXT  

International Normalized Ratio Increase Before Warfarin-Associated Hemorrhage: Brief and Subtle
Kucher et al.
Arch Intern Med 2004;164:2176-2179.
ABSTRACT | FULL TEXT  

The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Ansell et al.
Chest 2004;126:204S-233S.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Levine et al.
Chest 2004;126:287S-310S.
ABSTRACT | FULL TEXT  

Anticoagulant-Related Bleeding in Older Persons With Atrial Fibrillation: Physicians' Fears Often Unfounded
Man-Son-Hing and Laupacis
Arch Intern Med 2003;163:1580-1586.
ABSTRACT | FULL TEXT  

Assessment of an Age-Adjusted Warfarin Initiation Protocol
Roberts et al.
The Annals of Pharmacotherapy 2003;37:799-803.
ABSTRACT | FULL TEXT  

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
Hirsh et al.
J Am Coll Cardiol 2003;41:1633-1652.
FULL TEXT  

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Hirsh et al.
Circulation 2003;107:1692-1711.
FULL TEXT  

Concomitant Coumarin-NSAID Therapy and Risk for Bleeding
Knijff-Dutmer et al.
The Annals of Pharmacotherapy 2003;37:12-16.
ABSTRACT | FULL TEXT  

Key questions concerning paracetamol and NSAIDs for osteoarthritis
Courtney and Doherty
Ann Rheum Dis 2002;61:767-773.
FULL TEXT  

Retroperitoneal haematoma after paracetamol increased anticoagulation
Andrews
Emerg. Med. J. 2002;19:84-85.
ABSTRACT | FULL TEXT  

Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin
Hylek et al.
ANN INTERN MED 2001;135:393-400.
ABSTRACT | FULL TEXT  

Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice?
Evans and Kalra
Arch Intern Med 2001;161:1443-1447.
ABSTRACT | FULL TEXT  

Coronary and myocardial effects of acetaminophen: protection during ischemia-reperfusion
Merrill et al.
Am. J. Physiol. Heart Circ. Physiol. 2001;280:H2631-H2638.
ABSTRACT | FULL TEXT  

Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh et al.
Chest 2001;119:8S-21S.
FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment
Levine et al.
Chest 2001;119:108S-121S.
FULL TEXT  

Osteoarthritis: New Insights. Part 2: Treatment Approaches
Felson et al.
ANN INTERN MED 2000;133:726-737.
ABSTRACT | FULL TEXT  

Anticoagulation for Chronic Atrial Fibrillation
Stern et al.
JAMA 2000;283:2901-2903.
FULL TEXT  

Prospective Study of the Outcomes of Ambulatory Patients With Excessive Warfarin Anticoagulation
Hylek et al.
Arch Intern Med 2000;160:1612-1617.
ABSTRACT | FULL TEXT  

Potentiation of Vitamin K Antagonists by High-Dose Intravenous Methylprednisolone
Costedoat-Chalumeau et al.
ANN INTERN MED 2000;132:631-635.
ABSTRACT | FULL TEXT  

State-of-the-Art Review: Warfarin Therapy: A Review of the Literature Since the Fifth American College of Chest Physicians' Consensus Conference on Antithrombotic Therapy
Lodwick
CLIN APPL THROMB HEMOST 1999;5:208-215.
 

Acetaminophen and Risk Factors for Excess Anticoagulation With Warfarin
Estrada et al.
JAMA 1998;280:695-697.
FULL TEXT  

Acetaminophen a Risk Factor for Overanticoagulation
Journal Watch Dermatology 1998;1998:15-15.
FULL TEXT  

Acetaminophen a Risk Factor for Overanticoagulation
Journal Watch Cardiology 1998;1998:4-4.
FULL TEXT  

Acetaminophen a Risk Factor for Overanticoagulation
JWatch General 1998;1998:1-1.
FULL TEXT  

Acetaminophen and Warfarin: Undesirable Synergy
Bell
JAMA 1998;279:702-703.
FULL TEXT